TNFSF10 and colorectal carcinoma: In this study, an rNDV carrying the human TRAIL gene was constructed and tested for its efficacy in TRAIL‐resistant CRC cells, specifically targeting HT‐29 cells that showed low responsiveness to the recombinant TRAIL protein‐based therapy.